跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 1,493 条关于
“MYB-NFIB”
全部
1,493
临床试验
817
药物
576
机构
11
资讯
89
2个月前
Rare Histological Subtypes of Triple-Negative Breast Cancer: A Comprehensive Review Highlights Diagnostic and Therapeutic Implications
去年
Rgenta Therapeutics Doses First Patients in Phase 1a/b Trial of MYB-Targeting RGT-61159 for Advanced Cancers
11个月前
Remix Therapeutics to Present Phase 1 Data of First-in-Class MYB RNA Degrader REM-422 for Adenoid Cystic Carcinoma at AACR Conference
3个月前
Passage Bio and Remix Therapeutics Announce Merger to Advance REM-422, an Oral mRNA Degrader Targeting MYB in Cancer
6个月前
FDA Grants Fast Track Designation to Remix Therapeutics' REM-422 for Adenoid Cystic Carcinoma Treatment
5个月前
Rgenta Therapeutics to Present Phase 1 Clinical Data on RNA-Targeting Cancer Drug RGT-61159 at ASCO 2026
去年
Rgenta Therapeutics Receives FDA Orphan Drug Designation for RGT-61159 in Adenoid Cystic Carcinoma Treatment
去年
Genetic Variants Linked to Vincristine-Induced Peripheral Neuropathy Identified
7个月前
RNA-Targeting Small Molecules Emerge as New Frontier in Drug Discovery with Major Pharma Partnerships
去年
Rgenta Therapeutics Unveils RSwitch Technology for Precise Control of Gene Therapy Expression
第 1 页,共 9 页
上一页
下一页